

SUPPLEMENTAL MATERIAL

Table S1. Associations of each clinical, laboratory and plaque characteristics with absolute change in lipid core volume and % lipid core.

Variable*	SD	Absolute change in lipid core volume			Absolute change in % lipid core		
		Δ^\dagger	95% CI	P-Value	Δ^\dagger	95% CI	P-Value
Lipid core ‡ §	\S	-3.1	(-7.2, 1.0)	0.14	-0.6	(-1.2, -0.1)	0.019
On-study ERN use	-	5.7	(-2.6, 13.9)	0.17	0.5	(-0.5, 1.6)	0.33
Age, years	9	0.0	(-4.2, 4.2)	0.99	0.4	(-0.2, 0.9)	0.17
Male sex	-	-2.0	(-17.2, 13.2)	0.79	0.0	(-1.9, 1.9)	0.99
Caucasian	-	11.0	(-6.1, 28.2)	0.20	2.3	(0.1, 4.4)	0.041
Total cholesterol, mg/dl	30	2.0	(-2.2, 6.2)	0.34	0.4	(-0.1, 0.9)	0.15
LDL cholesterol, mg/dl	26	0.8	(-3.3, 5.0)	0.68	0.2	(-0.3, 0.8)	0.43
Triglycerides ‡ , log(mg/dl)	0.5	1.8	(-2.5, 6.1)	0.41	0.3	(-0.2, 0.9)	0.27
HDL cholesterol, mg/dl	5	3.2	(-0.9, 7.3)	0.12	0.5	(-0.1, 1.0)	0.077
ApoB, mg/dl	24	1.8	(-2.4, 6.1)	0.40	0.3	(-0.2, 0.9)	0.28
ApoA-1, mg/dl	16	1.9	(-2.4, 6.1)	0.38	0.2	(-0.4, 0.7)	0.55
Lipoprotein(a) ‡ , log(nmol/L)	2.2	5.0	(0.9, 9.0)	0.018	0.7	(0.1, 1.2)	0.012
Calcification	-	8.5	(-0.1, 17.1)	0.051	1.0	(-0.2, 2.1)	0.094
Intraplaque hemorrhage	-	27.2	(15.4, 39.0)	<0.001	4.3	(3.1, 5.5)	<0.001

ERN: extended-release niacin, LDL: low-density lipoprotein, HDL: high-density lipoprotein.

* Linear regression model with the baseline lipid core variable (log-transformed) and on-study ERN use;

† Difference in annualized absolute change of lipid core volume or % lipid core per 1-SD increase (continuous baseline variables) or between groups (categorical baseline variables);

‡ Log-transformed prior to inclusion in the model;

§ Baseline lipid core volume for change in lipid core volume (SD: 2 log(mm³)) and baseline % lipid core for change in % lipid core (SD: 1.4 log(%)).